Advertisement
American Journal of Kidney Diseases

Diagnosis and Management of Iron Deficiency in CKD: A Summary of the NICE Guideline Recommendations and Their Rationale

Published:January 04, 2016DOI:https://doi.org/10.1053/j.ajkd.2015.11.012
      The UK-based National Institute for Health and Care Excellence (NICE) has updated its guidance on iron deficiency and anemia management in chronic kidney disease. This report outlines the recommendations regarding iron deficiency and their rationale. Serum ferritin alone or transferrin saturation alone are no longer recommended as diagnostic tests to assess iron deficiency. Red blood cell markers (percentage hypochromic red blood cells, reticulocyte hemoglobin content, or reticulocyte hemoglobin equivalent) are better than ferritin level alone at predicting responsiveness to intravenous iron. When red blood cell markers are not available, a combination of transferrin saturation < 20% and ferritin level < 100 ng/mL is an alternative. In comparisons of the cost-effectiveness of different iron status testing and treatment strategies, using percentage hypochromic red blood cells > 6% was the most cost-effective strategy for both hemodialysis and nonhemodialysis patients. A trial of oral iron replacement is recommended in people not receiving an erythropoiesis-stimulating agent (ESA) and not on hemodialysis therapy. For children receiving ESAs, but not treated by hemodialysis, oral iron should be considered. In adults and children receiving ESAs and/or on hemodialysis therapy, intravenous iron should be offered. When giving intravenous iron, high-dose low-frequency administration is recommended. For all children and for adults receiving in-center hemodialysis, low-dose high-frequency administration may be more appropriate.

      Index Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Kidney Diseases
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. National Clinical Guideline Centre. Anaemia management in chronic kidney disease: update 2015. NICE guideline 8. National Institute for Health and Care Excellence (NICE). Updated 2015. http://www.nice.org.uk/guidance/ng8. Accessed June 3, 2015.

        • Padhi S.
        • Glenn J.
        • Pordes B.A.J.
        • Thomas M.E.
        Management of anaemia in chronic kidney disease: summary of updated NICE guidance.
        BMJ. 2015; 350: h2258
        • Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group
        KDIGO clinical practice guideline for anemia in chronic kidney disease.
        Kidney Int Suppl. 2012; 2: 279-335
        • Locatelli F.
        • Barany P.
        • Covic A.
        • et al.
        Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement.
        Nephrol Dial Transplant. 2013; 28: 1346-1359
        • Kliger A.S.
        • Foley R.N.
        • Goldfarb D.S.
        • et al.
        KDOQI US commentary on the 2012 KDIGO clinical practice guideline for anemia in CKD.
        Am J Kidney Dis. 2013; 62: 849-859
      2. Chung M, Moorthy D, Hadar N, Salvi P, Iovin RC, Lau J. Biomarkers for assessing and managing iron deficiency anemia in late-stage chronic kidney disease. Comparative Effectiveness Review No. 83. AHRQ Publication No. 12(13)-EHC140-EF. Agency for Healthcare Research and Quality. Updated 2012. http://effectivehealthcare.ahrq.gov/ehc/products/295/1281/CER83_AnemiaBiomarkers_ExecutiveSummary_20121010.pdf. Accessed March 29, 2015.

        • Looker A.C.
        • Dallman P.R.
        • Carroll M.D.
        • Gunter E.W.
        • Johnson C.L.
        Prevalence of iron deficiency in the United States.
        JAMA. 1997; 277: 973-976
        • Yang J.Y.
        • Lee T.C.
        • Montez-Rath M.E.
        • et al.
        Trends in acute nonvariceal upper gastrointestinal bleeding in dialysis patients.
        J Am Soc Nephrol. 2012; 23: 495-506
        • Eschbach J.W.
        • Cook J.D.
        • Scribner B.H.
        • Finch C.A.
        Iron balance in hemodialysis patients.
        Ann Intern Med. 1977; 87: 710-713
        • Martin-del-Campo F.
        • Batis-Ruvalcaba C.
        • Gonzalez-Espinoza L.
        • et al.
        Dietary micronutrient intake in peritoneal dialysis patients: relationship with nutrition and inflammation status.
        Perit Dial Int. 2012; 32: 183-191
        • Peters H.P.
        • Laarakkers C.M.
        • Pickkers P.
        • et al.
        Tubular reabsorption and local production of urine hepcidin-25.
        BMC Nephrol. 2013; 14: 70
        • Valenti L.
        • Girelli D.
        • Valenti G.F.
        • et al.
        HFE mutations modulate the effect of iron on serum hepcidin-25 in chronic hemodialysis patients.
        Clin J Am Soc Nephrol. 2009; 4: 1331-1337
        • Nissenson A.R.
        • Dylan M.L.
        • Griffiths R.I.
        • Yu H.T.
        • Dubois R.W.
        Septicemia in patients with ESRD is associated with decreased hematocrit and increased use of erythropoietin.
        Clin J Am Soc Nephrol. 2006; 1: 505-510
        • Panichi V.
        • Rosati A.
        • Bigazzi R.
        • et al.
        Anaemia and resistance to erythropoiesis-stimulating agents as prognostic factors in haemodialysis patients: results from the RISCAVID study.
        Nephrol Dial Transplant. 2011; 26: 2641-2648
        • Ford B.A.
        • Coyne D.W.
        • Eby C.S.
        • Scott M.G.
        Variability of ferritin measurements in chronic kidney disease; implications for iron management.
        Kidney Int. 2009; 75: 104-110
        • Rambod M.
        • Kovesdy C.P.
        • Kalantar-Zadeh K.
        Combined high serum ferritin and low iron saturation in hemodialysis patients: the role of inflammation.
        Clin J Am Soc Nephrol. 2008; 3: 1691-1701
      3. National Clinical Guideline Centre. Anaemia management in chronic kidney disease: update 2015. NICE guideline 8: Appendices. National Institute for Health and Care Excellence (NICE). Updated 2015. http://www.nice.org.uk/guidance/NG8/evidence. Accessed June 3, 2015.

        • de Goeij M.C.M.
        • Meuleman Y.
        • van Dijk S.
        • et al.
        Haemoglobin levels and health-related quality of life in young and elderly patients on specialized predialysis care.
        Nephrol Dial Transplant. 2014; 29: 1391-1398
        • Coyne D.W.
        • Kapoian T.
        • Suki W.
        • et al.
        Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study.
        J Am Soc Nephrol. 2007; 18: 975-984
      4. Macdougall IC. KDIGO Controversies Conference on Iron Management in Chronic Kidney Disease. Iron Management: New Strategies Currently Under Investigation. Kidney Disease: Improving Global Outcomes. Updated 2014. http://www.kdigo.org/ControConf/Iron%20Management%202014/Macdougall_New%20Iron%20Management%20Strategies.pdf. Accessed May 23, 2015.

        • Richardson D.
        • Bartlett C.
        • Will E.J.
        Optimizing erythropoietin therapy in hemodialysis patients.
        Am J Kidney Dis. 2001; 38: 109-117
        • Tolman C.
        • Richardson D.
        • Bartlett C.
        • Will E.
        Structured conversion from thrice weekly to weekly erythropoietic regimens using a computerized decision-support system: a randomized clinical study.
        J Am Soc Nephrol. 2005; 16: 1463-1470
        • Will E.J.
        • Richardson D.
        • Tolman C.
        • Bartlett C.
        Development and exploitation of a clinical decision support system for the management of renal anaemia.
        Nephrol Dial Transplant. 2007; 22: iv31-iv36
      5. BNF Paediatric Formulary Committee. British National Formulary for Children (BNFC) May 2015. BMJ Group, the Royal Pharmaceutical Society of Great Britain, and RCPCH Publications Ltd. Updated 2015. http://www.bnf.org/products/bnf-online/. Accessed May 24, 2015.

        • Brookhart M.A.
        • Freburger J.K.
        • Ellis A.R.
        • Wang L.
        • Winkelmayer W.C.
        • Kshirsagar A.V.
        Infection risk with bolus versus maintenance iron supplementation in hemodialysis patients.
        J Am Soc Nephrol. 2013; 24: 1151-1158
      6. Zager P, Meyer KB, Ladik V, Paine S, Johnson D. Anemia management using computerized decision support. Updated 2013. http://www.nephrologynews.com/articles/computerized-decision-support-for-anemia-management-in-hemodialysis-patients. Accessed March 30, 2015.

        • Irving M.
        • Craig J.
        • Gallagher M.
        • et al.
        Implementing iron management clinical practice guidelines in patients with chronic kidney disease having dialysis.
        Med J Aust. 2006; 185: 310-314
        • Yong K.
        • Kairaitis L.
        Effects of proactive iron and erythropoiesis-stimulating agent protocol implementation on achieving clinical guideline targets for anaemia in a satellite haemodialysis patient cohort.
        Nephrology (Carlton). 2010; 15: 288-293
      7. European Medicines Agency. New recommendations to manage risk of allergic reactions with intravenous iron-containing medicines. Updated 2013. http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/IV_iron_31/WC500151308.pdf. Accessed March 4, 2015.

      8. Committee for Medicinal Products for Human Use EMA. Annex II. Scientific conclusions and grounds for variation to the terms of the marketing authorisations. Overall summary of the scientific evaluation of intravenous iron containing medicinal products. European Medicines Agency. Updated 2013. http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/IV_iron_31/WC500150773.pdf. Accessed March 4, 2015.

        • Wysowski D.K.
        • Swartz L.
        • Borders-Hemphill B.V.
        • Goulding M.R.
        • Dormitzer C.
        Use of parenteral iron products and serious anaphylactic-type reactions.
        Am J Hematol. 2010; 85: 650-654
      9. US Food and Drug Administration. FDA strengthens warnings and changes prescribing instructions to decrease the risk of serious allergic reactions with anemia drug Feraheme (ferumoxytol). Updated 2015. http://www.fda.gov/drugs/drugsafety/drugsafetypodcasts/ucm440823.htm. Accessed October 26, 2015.

        • Canavese C.
        • Bergamo D.
        • Ciccone G.
        • et al.
        Validation of serum ferritin values by magnetic susceptometry in predicting iron overload in dialysis patients.
        Kidney Int. 2004; 65: 1091-1098
        • Ferrari P.
        • Kulkarni H.
        • Dheda S.
        • et al.
        Serum iron markers are inadequate for guiding iron repletion in chronic kidney disease.
        Clin J Am Soc Nephrol. 2011; 6: 77-83
        • Rostoker G.
        • Griuncelli M.
        • Loridon C.
        • et al.
        Hemodialysis-associated hemosiderosis in the era of erythropoiesis-stimulating agents: a MRI study.
        Am J Med. 2012; 125: 991-999
        • Kalantar-Zadeh K.
        • Regidor D.L.
        • McAllister C.J.
        • Michael B.
        • Warnock D.G.
        Time-dependent associations between iron and mortality in hemodialysis patients.
        J Am Soc Nephrol. 2005; 16: 3070-3080
        • Miskulin D.C.
        • Tangri N.
        • Bandeen-Roche K.
        • et al.
        Intravenous iron exposure and mortality in patients on hemodialysis.
        Clin J Am Soc Nephrol. 2014; 9: 1930-1939
        • Vaziri N.D.
        Epidemic of iron overload in dialysis population caused by intravenous iron products: a plea for moderation.
        Am J Med. 2012; 125: 951-952